2023 World Conference on Lung Cancer (Posters)-EP06.03. Clinical Impact of Next-Generation Sequencing in KRAS-Mutated Non-Small Cell Lung Cancer Patients: a Single-Center Experience

EP06.03. Clinical Impact of Next-Generation Sequencing in KRAS-Mutated Non-Small Cell Lung Cancer Patients: a Single-Center Experience - PDF(Slides)

Back to course

Pdf Summary

This study evaluated the clinical impact of next-generation sequencing (NGS) in non-small cell lung cancer (NSCLC) patients with KRAS mutations. The researchers conducted a retrospective chart review of NSCLC patients at a hospital in Greece who received systemic therapy. The KRAS mutations were diagnosed using tumor tissue-based NGS. The clinicopathological characteristics of the patients were analyzed, and co-mutations in genes other than KRAS were also detected.<br /><br />A total of 23 patients were included in the study, with a median age at NSCLC diagnosis of 62 years. The majority of patients were smokers (90.5%), and 69.6% had de novo metastatic disease at the time of diagnosis. Adenocarcinoma was the most common histologic type (95.7%).<br /><br />The KRAS mutations detected in these patients included G12C (52.2%), G12V (26.1%), G12D (13.0%), G12S (4.3%), and G13C (4.3%). Co-mutations in genes other than KRAS, such as MET and TP53, were detected in 69.6% of patients.<br /><br />After a median follow-up of 14.6 months, the median progression-free survival was 13.6 months, and the median overall survival was not reached. This suggests that NGS allowed for the detection of additional genomic alterations with potential clinical significance in the majority of KRAS-mutated NSCLC patients.<br /><br />In conclusion, the use of NGS in KRAS-mutated NSCLC patients can provide valuable information on additional genomic alterations that may have prognostic or predictive significance. These findings contribute to the growing body of evidence supporting the clinical utility of NGS in NSCLC management.

Asset Subtitle

Emmanouil Panagiotou

Meta Tag

Speaker Emmanouil Panagiotou

Topic Pathology & Biomarkers: Genetic Biomarkers

Keywords

next-generation sequencing

non-small cell lung cancer

KRAS mutations

retrospective chart review

tumor tissue-based NGS

co-mutations

adenocarcinoma

progression-free survival

genomic alterations

clinical utility